Advent International plans to acquire a 50.1% stake in Indian pharmaceutical company Suven Pharmaceuticals for $767 million, with an aim to merge it with its subsidiary Cohance Life Sciences to create a leading player in the CDMO market.

Target Company Overview

Suven Pharmaceuticals is a leading Indian Contract Development and Manufacturing Organization (CDMO), specializing in the development and manufacturing of pharmaceutical intermediates, active ingredients, specialty chemicals, and formulated drugs. The company operates primarily in India, the United States, and Europe, with a robust market presence. As of October 2023, Suven has a market capitalization of approximately $1.5 billion and employs around 1,200 personnel.

Founded in 2018 and headquartered in Hyderabad, Telangana, Suven aims to serve global life sciences and fine chemical majors. With a focus on drug development services, the company maintains a diverse portfolio that includes bulk drugs, intermediates, and fine chemicals tailored to regional markets.

Industry Overview in India

The Indian pharmaceutical industry is one of the fastest-growing sectors globally, projected to triple in size over the next decade. This growth is fueled by increasing dome